ScholarIQanswers from OpenAlex & ORCID
Lisa Bodei
ResearcherPublications, citations & collaboration network
Lisa Bodei is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Lisa Bodei have?
ScholarIQindexed works
Lisa Bodei has 348 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Lisa Bodei have?
ScholarIQcitation count
Lisa Bodei has 16,404 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Lisa Bodei?
ScholarIQh-index
Lisa Bodei has an h-index of 72 in OpenAlex.
What is the i10-index of Lisa Bodei?
ScholarIQi10-index
Lisa Bodei has an i10-index of 175 in OpenAlex.
What is the ORCID of Lisa Bodei?
ScholarIQorcid
The ORCID for Lisa Bodei is on the source record.
What is the OpenAlex record for Lisa Bodei?
ScholarIQopenalex
The OpenAlex for Lisa Bodei is on the source record.
What are the most-cited papers on Lisa Bodei?
ScholarIQmost cited works
Radiopharmaceutical therapy in cancer: clinical advances and challenges
George Sgouros, Lisa Bodei, Michael R. McDevitt, Jessie R. Nedrow
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
John J. Zaknun, Lisa Bodei, Jan Mueller‐Brand, Marianne E. Pavel, Richard P. Baum, Dieter Hörsch, M. Sue O’Dorisio, T. M. O’Dorisiol, James R. Howe, Marta Cremonesi, Dik J. Kwekkeboom
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
Lisa Bodei, Mark Kidd, Giovanni Paganelli, Chiara Maria Grana, Ignat Drozdov, Marta Cremonesi, Christopher Lepensky, Dik J. Kwekkeboom, Richard P. Baum, Eric P. Krenning, Irvin M. Modlin
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
Lisa Bodei, Marta Cremonesi, Mahila Ferrari, Monica Pacifici, Chiara Maria Grana, Mirco Bartolomei, Silvia M. Baio, Maddalena Sansovini, Giovanni Paganelli
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Lisa Bodei, Marta Cremonesi, Chiara Maria Grana, Nicola Fazio, Simona Iodice, Silvia M. Baio, Mirco Bartolomei, Dario Lombardo, Mahila Ferrari, Maddalena Sansovini, Marco Chinol, Giovanni Paganelli